Discrepancies between immunohistochemistry and fluorescence in situ hybridization for HER-2 testing in breast cancer: The role of a quality assurance program on a cohort of 3564 patients

Journal article

Peer reviewed

H. Yaziji, T. S. Barry, L. C. Goldstein, H. H. Hwang, A. W. Hing and A. M. Gown

Journal of clinical oncology, Vol.22(14_suppl), pp.679-679

15/07/2004

Abstract

Abstract only

1 Record Views

Title: Discrepancies between immunohistochemistry and fluorescence in situ hybridization for HER-2 testing in breast cancer: The role of a quality assurance program on a cohort of 3564 patients
Creators - without role: H. Yaziji - PhenoPath Laboratories, Seattle, WA
T. S. Barry - PhenoPath Laboratories, Seattle, WA
L. C. Goldstein - PhenoPath Laboratories, Seattle, WA
H. H. Hwang - PhenoPath Laboratories, Seattle, WA
A. W. Hing - PhenoPath Laboratories, Seattle, WA
A. M. Gown - PhenoPath Laboratories, Seattle, WA
Publication Details: Journal of clinical oncology, Vol.22(14_suppl), pp.679-679
Identifiers: 9941722408331
Academic Unit: King Abdullah University of Science & Technology
Language: English
Resource Type: Journal article